| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
Purity: ≥98%
SRT2183 (SRT 2183; SRT-2183) is a novel and potent small-molecule activator of the sirtuin subtype1-(SIRT1, EC50 =0.36 μM) developed by Sirtris Pharmaceuticals as therapeutics for the treatment of type 2 diabetes and potentially leukemia as well. SRT2183 resembles resveratrol in potency but functions similarly in the body to another SIRT1 activator, SRT1720. It has been observed in animal studies to enhance insulin sensitivity, decrease liver, muscle, and fat tissue's plasma glucose levels, and boost mitochondrial and metabolic activity. The assertion that SRT2183 activates SIRT1 has been contested and then reaffirmed, though.
| Targets |
SIRT1 ( EC1.5 = 0.36 μM )
|
||
|---|---|---|---|
| ln Vitro |
|
||
| ln Vivo |
|
||
| Cell Assay |
BMMs are harvested, plated, and 24-hour later, non-adherent cells were replated in α-MEM/15% FBS/5% M-CSF at a density of 20,000 cells/well. In order to assess cell proliferation, 72 hours after plating, cells are treated with SRT2183 or a vehicle. Then, 48 hours after SRT2183 or vehicle administration, BrdU reagent is added in accordance with manufacturer's instructions to assess cell proliferation three days after plating.
|
||
| Animal Protocol |
|
||
| References |
| Molecular Formula |
C27H24N4O2S
|
|
|---|---|---|
| Molecular Weight |
468.57
|
|
| Exact Mass |
468.16
|
|
| Elemental Analysis |
C, 69.21; H, 5.16; N, 11.96; O, 6.83; S, 6.84
|
|
| CAS # |
1001908-89-9
|
|
| Related CAS # |
|
|
| Appearance |
White solid powder
|
|
| SMILES |
C1CN(C[C@@H]1O)CC2=CSC3=NC(=CN23)C4=CC=CC=C4NC(=O)C5=CC6=CC=CC=C6C=C5
|
|
| InChi Key |
MUFSINOSQBMSLE-JOCHJYFZSA-N
|
|
| InChi Code |
InChI=1S/C27H24N4O2S/c32-22-11-12-30(15-22)14-21-17-34-27-29-25(16-31(21)27)23-7-3-4-8-24(23)28-26(33)20-10-9-18-5-1-2-6-19(18)13-20/h1-10,13,16-17,22,32H,11-12,14-15H2,(H,28,33)/t22-/m1/s1
|
|
| Chemical Name |
N-[2-[3-[[(3R)-3-hydroxypyrrolidin-1-yl]methyl]imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]naphthalene-2-carboxamide
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1342 mL | 10.6708 mL | 21.3415 mL | |
| 5 mM | 0.4268 mL | 2.1342 mL | 4.2683 mL | |
| 10 mM | 0.2134 mL | 1.0671 mL | 2.1342 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
 |
|---|
 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA